De Novo Formation and Ultra-Structural Characterization of a Fiber-Producing Human Hair Follicle Equivalent In Vitro

    January 2011 in “ Journal of biotechnology ”
    G Lindner, Reyk Horland, Ilka Wagner, Beren Ataç, Roland Lauster
    TLDR Scientists recreated human hair follicles in the lab that can grow hair.
    The study described the successful in vitro creation and detailed ultra-structural analysis of a human hair follicle equivalent capable of producing fibers. This technology, developed by researchers at Technische Universität Berlin, was subject to a patent application and involved contributions from TissUse GmbH. The research was supported by various grants and involved collaboration with multiple experts. The findings suggested potential applications in drug testing and regenerative therapies, highlighting the importance of developing robust hair follicle models for experimental and therapeutic purposes.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Community Posts Join

    6 / 1000+ results

      community Natural Remedies: Polyphenols and Hair Loss

       19 upvotes 5 years ago
      Natural remedies to treat hair loss, such as polyphenols, apple peel extract, grape seed extract, green tea extract, peppermint oil, pumpkin seed oil, apigenin, Ginkgo biloba, red clover extract, olive leaf extract, Ecklonia Cava and Grateloupia elliptica. In addition, terpenes, carotenoids, and tocopherols were discussed as potential treatments.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Related Research

    4 / 4 results